Integrated multi-OMICs for the identification of novel therapies for alcoholic hepatitis

Hosted by Javier Crespo

Ramon Bataller graduated from Medicine at the University of Valencia in 1989, completed the residency in Gastroenterology in the Hospital Clinic of Barcelona in 1994. He performed and defended his doctoral Thesis from 1995-2000 on the role of vasoactive substances in liver fibrosis. Between 2000 and 2003, he completed a research fellowship in hepatology at UNC-Chapel Hill with Prof. David A. Brenner. During this period, he investigated the role of angiotensin II and NADPH oxidase in liver fibrosis. From 2003-2011, he was senior physician at the Liver Unit of the Hospital Clinic in Barcelona and coordinated the management of patients with alcoholic liver disease (ALD). During this period, he performed several translational studies in alcoholic hepatitis and identified several novel targets for therapy. In 2011, he joined the University of North Carolina at Chapel Hill and led an international effort to develop the first histological classification of alcoholic hepatitis (AHHS) and described the role of systemic inflammation on renal dysfunction. From 2011-2017, he was the overall PI of an NIAAA-funded international consortium to study alcoholic hepatitis (InTeam). From 2017, he is serving as Chief of Hepatology at the University of Pittsburgh Medical Center and he is co-PI of the NIAAA-funded AlcHepNet network that involves translational studies and clinical trials. Besides clinical and research activities, he is very active in the national and international arena with multiple grand rounds and international talks on alcoholic hepatitis and in 2015-2016 I served as chair of the Special Interest group for ALD in the AASLD. During the last years, he has worked in integrated OMICs in patients with ALD. Moreover, he recently created an international network (Global AlcHep) to study alcoholic hepatitis and has generated several studies using big data.